Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Richard Moxon photo superimposed on Buchanan Medal

The 2022 Royal Society Buchanan Medal has been awarded to Richard Moxon, Emeritus Professor of Paediatrics, in recognition of his work helping pioneer the field of molecular microbiology. The Buchanan Medal is awarded annually for distinguished contributions to the biomedical sciences. 

Professor Moxon was asked by the late Sir David Weatherall to be one of the founding scientists of the then Institute of Molecular Medicine (now the MRC WIMM). During his time here, Professor Moxon founded the Oxford Vaccine Group. He and his team also identified the genetics of the bacteria Haemophilus influenzae type b (Hib), which is the main cause of childhood meningitis. This led to a vaccine for meningitis being developed and rolled out as part of the infant immunisation programme in the UK in 1992.

Professor Moxon's group went on to sequence the genome of Hib and was one of the first groups in the world to demonstrate that this technique can be used to find new targets for vaccines. This technology underpins the development of the AstraZeneca/Oxford University vaccine for COVID-19.

Commenting on his award win, Professor Moxon said, "I am very proud to receive this award, because the Royal Society champions excellence in research. I am also humbled, because my career was built on the shoulders of giants who have mentored, supported and encouraged me."

Many congratulations to Professor Moxon!

Read more about Professor Moxon's work.

Read more about the Royal Society Buchanan Medal

 

Similar stories

September is Childhood Cancer Awareness Month

September is Childhood Cancer Awareness Month, where our Childhood Leukaemia research group have taken action to help raise awareness for this cause.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from the Holländer Group has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Project funding for personalised childhood cancer treatments

Funding from the Azaylia Foundation will support the Scientific Advances for Infant Leukaemia (SAIL) programme.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

$2m awarded to explore the role of ancestry in vaccine response

The Lymph nodE single-cell Genomics AnCestrY (LEGACY) Network will create an ethnically diverse single-cell atlas of the response to commonly used vaccines such as flu vaccines with a focus on responses in lymph nodes.

New atlas revealed of bone marrow haematopoiesis during development

A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.